furmonertinib

Key facts

Mechanism of action

Epidermal growth factor receptor erbB1 inhibitor

Primary target: Epidermal growth factor receptor

Approval history

1. FURMO-006 Phase 3 · ArriVent BioPharma · Advanced or Metastatic Non-Small-Cell Lung Cancer With Epide
2. furmonertinib 240 mg oral, daily Phase 3 · ArriVent BioPharma · Metastatic Non-Small Cell Lung Cancer
3. Furmonertinib Phase 2 · Peking University Biologics · Adenocarcinoma of Lung
4. Furmonertinib Phase 2 · Shanghai University of · Lung Adenocarcinoma Stage III
5. Furmonertinib Phase 2 · Chinese Academy of · Lung Adenocarcinoma Stage III
6. Furmonertinib Phase 2 · First People's Hospital · Non-Small Cell Lung Cancer
7. Furmonertinib in combination with Anrotinib and chemotherapy Phase 2 · Chinese Academy of · Lung Cancer (NSCLC)
8. furmonertinib Phase 2 · Sun Yat-sen University · Non-small Cell Lung Cancer Metastatic

1. erlotinib hydrochloride Epidermal growth factor receptor erbB1 inhibitor
2. lapatinib ditosylate Receptor protein-tyrosine kinase erbB-2 inhibitor
3. mobocertinib Antineoplastic and immunomodulating agents (L01)
4. mobocertinib succinate Epidermal growth factor receptor erbB1 inhibitor
5. neratinib maleate Receptor protein-tyrosine kinase erbB-2 inhibitor
6. afatinib dimaleate Epidermal growth factor receptor erbB1 inhibitor

Frequently asked questions